To address the ongoing COVID-19 related iodinated contrast media product shortage, Iomeron will be temporarily available in the US starting at the end of August 2022.
All articles by Brian Park, PharmD
The designation was based on data from 2 phase 2 proof-of-concept studies that evaluated VX-548 for acute pain following abdominoplasty or bunionectomy surgery.
A 50 mcg booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against Omicron subvariants BA.4 and BA.5 in adults.
First Relief is a wearable PENS device that is placed behind the ear.
PLG0206 is an investigational, broad-spectrum, anti-biofilm, anti-infective peptide therapeutic.
The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in 152 adults with uncontrolled gout.
RoxyBond is an abuse-deterrent formulation of immediate-release oxycodone that features a unique abuse-deterrent technology.
Patients prescribed the 30 mg dose who receive the 60 mg dose may potentially be at risk for overdose and death.
Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.
Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.